10.3978/j.issn.1000-9604.2015.06.08
Phase Ⅰ dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer
27
The study was supported by the Chinese National Major Project for New Drug Innovation2008ZX09312,2012ZX09303012;we thank Bayer HealthCare Ltd.for partial financial support and Content Ed Net Shanghai Co.,Ltd.for editorial support
2015-08-05(万方平台首次上网日期,不代表论文的发表时间)
共8页
239-246